介导威氏气单胞菌溶血素成熟的第二种细胞外蛋白酶。
Second extracellular protease mediating maturation of Vibrio mimicus hemolysin.
机构信息
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1, Tsushima-Naka, Kita-Ku, Okayama, Okayama, 700-8530, Japan.
出版信息
World J Microbiol Biotechnol. 2022 Oct 22;38(12):241. doi: 10.1007/s11274-022-03436-9.
Vibrio mimicus is a bacterium that causes gastroenteritis in humans. This pathogen produces an enterotoxic hemolysin called V. mimicus hemolysin (VMH), which is secreted extracellularly as an inactive 80-kDa protoxin and converted to a 66-kDa mature toxin through cleavage between Arg and Ser. The 56-kDa serine protease termed V. mimicus trypsin-like protease (VmtA) is known to mediate this maturating process. However, some strains including strain ES-20 does not possess the vmtA gene. In the present study, the vmtA-negative strains were found to have a replaced gene that encodes a 43-kDa (403 aa) precursor of a serine protease designated by VmtX (V. mimicus trypsin-like protease X). To examine whether VmtX is also involved in the maturation of VMH, VmtX was isolated from the culture supernatant of V. mimicus strain NRE-20, a metalloprotease-negative mutant constructed from strain ES-20. Concretely, the culture supernatant was fractionated with 70% saturated ammonium sulfate and subjected to affinity column chromatography using a HiTrap Benzamidine FF column. The analysis of the N-terminal amino acid sequences of the proteins in the obtained VmtX preparation indicated that the 39-kDa protein was active VmtX consisting of 371 aa (Ile-Ser). The VmtX preparation was found to activate pro-VMH through generation of the 66-kDa protein. Additionally, treatment of the VmtX preparation with serine protease inhibitors, such as leupeptin and phenylmethylsulfonyl fluoride, significantly suppressed the activities to hydrolyze the specific peptide substrate and to synthesize the 66-kDa toxin. These findings indicate that VmtX is the second protease that mediats the maturation of VMH.
韦荣球菌是一种引起人类肠胃炎的细菌。这种病原体产生一种名为韦荣球菌溶血素(VMH)的肠毒素溶血素,它以前体 80kDa 的形式分泌到细胞外,通过精氨酸和丝氨酸之间的切割转化为成熟的 66kDa 毒素。已知 56kDa 的丝氨酸蛋白酶称为韦荣球菌胰蛋白酶样蛋白酶(VmtA)介导这种成熟过程。然而,一些菌株,包括 ES-20 菌株,不具有 vmtA 基因。在本研究中,发现 vmtA 阴性菌株具有一个替换基因,该基因编码一种丝氨酸蛋白酶的 43kDa(403aa)前体,命名为 VmtX(韦荣球菌胰蛋白酶样蛋白酶 X)。为了研究 VmtX 是否也参与 VMH 的成熟,从 ES-20 菌株构建的金属蛋白酶阴性突变株 NRE-20 的培养上清液中分离出 VmtX。具体来说,用 70%饱和硫酸铵对培养上清液进行分级,然后使用 HiTrap Benzamidine FF 柱进行亲和层析。获得的 VmtX 制剂中蛋白质的 N 末端氨基酸序列分析表明,39kDa 蛋白是由 371aa(Ile-Ser)组成的活性 VmtX。发现 VmtX 制剂通过产生 66kDa 蛋白来激活前 VMH。此外,用丝氨酸蛋白酶抑制剂,如亮肽素和苯甲基磺酰氟处理 VmtX 制剂,可显著抑制水解特异性肽底物和合成 66kDa 毒素的活性。这些发现表明 VmtX 是第二种介导 VMH 成熟的蛋白酶。